EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinicopathological and Prognostic Implications of Epithelial‐to‐Mesenchymal Transition‐Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study

Ahmad Machmouchi, Lama Zahreddine, Jessica Aoun, Noura Abbas iD, Maya Charafeddine, Laudy Chehade, Charbel Elias, Ziad El Husseini, Sally Temraz, Deborah Mukherji, Mohamad Khalife iD, Walid Faraj iD und 4 weitere

Cancer Reports · 2026-05 · 9 (5)

DOI: 10.1002/cnr2.70565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 03.05.2026. Verfasst von Ahmad Machmouchi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology/Oncology, Naef K. Basile Cancer Institute, American University of Beirut, Beirut, Lebanon. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Pancreatic Neoplasms, Vimentin, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is the sixth leading cause of global cancer death. The process of epithelial‐to‐mesenchymal transition (EMT) is a key driver of early progression and metastasis in PDAC.

Aim

Our study aimed to explore the correlation between the expression of EMT markers and survival outcomes. Methods and Results We conducted a retrospective longitudinal study on patients diagnosed with resectable PDAC between January 2005 and June 2019, with a 5‐year follow‐up for survival analysis. Immunohistochemical staining was performed to assess E‐cadherin and vimentin expression. EMT was defined as the presence of high Vimentin (mesenchymal) expression combined with low E‐cadherin (epithelial) expression. The study cohort included 135 patients with resectable PDAC, with 86 males (63.7%) and a mean age of 63.5 years (SD 10.1); most tumors were grade 2 (84, 64.6%). Cox regression analysis revealed that Vimentin expression ( p = 0.005), positive margin ( p = 0.008), and absence of metformin intake ( p = 0.023) were independent predictors of poor OS. High Vimentin was associated with lower median OS (17.0 ± 4.4 vs. 25.8 ± 2.3 months, p = 0.037) and DFS (8.6 ± 1.2 vs. 13.0 ± 2.3 months, p = 0.014), compared to low Vimentin, and it was correlated with higher tumor grade ( p = 0.028) and metastasis rate ( p = 0.032). The poorest outcomes were observed when high Vimentin was coupled with low E‐cadherin (median OS of 12.6 ± 4.7 vs. 24.5 ± 2.1 months, p = 0.038; median DFS of 9.5 ± 0.5 vs. 10.8 ± 2.1 months, p = 0.029), compared to the rest of the population.

Conclusion

Our findings showed that Vimentin overexpression and the EMT phenomenon are strongly associated with poor OS and DFS in resectable PDAC, underscoring their potential as prognostic biomarkers and therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionPancreatic NeoplasmsVimentinCarcinoma, Pancreatic DuctalBiomarkers, TumorHumansMaleFemaleRetrospective StudiesMiddle AgedPrognosisAgedCadherinsImmunohistochemistryLongitudinal StudiesAntigens, CDPancreatectomy

Stichwörter der Autor:innen

EMTE‐cadherinPDACimmunohistochemistrypancreatic cancerpancreatic ductal adenocarcinomavimentin

Substanzen

VimentinBiomarkers, TumorCadherinsVIM protein, humanAntigens, CDCDH1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology/Oncology, Naef K. Basile Cancer Institute, American University of Beirut, Beirut, Lebanon.
  • Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon.
  • Department of Surgery, American University of Beirut, Beirut, Lebanon.

ORCID-Profile: Noura Abbas, Mohamad Khalife, Walid Faraj, Ali Shamseddine

Zitieren

APA

Machmouchi, A., Zahreddine, L., Aoun, J., Abbas, N., Charafeddine, M., Chehade, L., Elias, C., El Husseini, Z., Temraz, S., Mukherji, D., Khalife, M., Faraj, W., Zaidan, A., Kadi, N., Tawil, A., & Shamseddine, A. (2026). Clinicopathological and Prognostic Implications of Epithelial‐to‐Mesenchymal Transition‐Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study. Cancer Reports, 9(5). https://doi.org/10.1002/cnr2.70565

Vancouver

Machmouchi A, Zahreddine L, Aoun J, Abbas N, Charafeddine M, Chehade L, et al. Clinicopathological and Prognostic Implications of Epithelial‐to‐Mesenchymal Transition‐Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study. Cancer Reports. 2026;9(5). doi:10.1002/cnr2.70565

BibTeX
@article{Machmouchi2026,
  author = {Machmouchi, Ahmad and Zahreddine, Lama and Aoun, Jessica and Abbas, Noura and Charafeddine, Maya and Chehade, Laudy and Elias, Charbel and El Husseini, Ziad and Temraz, Sally and Mukherji, Deborah and Khalife, Mohamad and Faraj, Walid and Zaidan, Amar and Kadi, Nayrose and Tawil, Ayman and Shamseddine, Ali},
  title = {Clinicopathological and Prognostic Implications of Epithelial‐to‐Mesenchymal Transition‐Related Immunohistochemical Markers in Resectable Pancreatic Cancer: A Retrospective Longitudinal Study},
  journal = {Cancer Reports},
  year = {2026},
  volume = {9},
  number = {5},
  doi = {10.1002/cnr2.70565}
}
Kostenlos starten →